Cargando…
Infant rhesus macaques immunized against SARS-CoV-2 are protected against heterologous virus challenge one year later
The U.S. Food and Drug Administration only gave emergency-use-authorization of the BNT162b2 and the mRNA-1273 SARS-CoV-2 vaccines for infants 6 months and older in June 2022. Yet, questions regarding the durability of vaccine efficacy, especially against emerging variants, in this age group remain....
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for the Advancement of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9765459/ https://www.ncbi.nlm.nih.gov/pubmed/36454813 http://dx.doi.org/10.1126/scitranslmed.add6383 |
_version_ | 1784853491769933824 |
---|---|
author | Milligan, Emma C. Olstad, Katherine Williams, Caitlin A. Mallory, Michael Cano, Patricio Cross, Kaitlyn A. Munt, Jennifer E. Garrido, Carolina Lindesmith, Lisa Watanabe, Jennifer Usachenko, Jodie L. Hopkins, Lincoln Immareddy, Ramya Lakshmanappa, Yashavanth Shaan Elizaldi, Sonny R. Roh, Jamin W. Sammak, Rebecca L. Pollard, Rachel E. Yee, JoAnn L. Herbek, Savannah Scobey, Trevor Miehlke, Dieter Fouda, Genevieve Ferrari, Guido Gao, Hongmei Shen, Xiaoying Kozlowski, Pamela A. Montefiori, David Hudgens, Michael G. Edwards, Darin K. Carfi, Andrea Corbett, Kizzmekia S. Graham, Barney S. Fox, Christopher B. Tomai, Mark Iyer, Smita S. Baric, Ralph Reader, Rachel Dittmer, Dirk P. Van Rompay, Koen K.A. Permar, Sallie R. De Paris, Kristina |
author_facet | Milligan, Emma C. Olstad, Katherine Williams, Caitlin A. Mallory, Michael Cano, Patricio Cross, Kaitlyn A. Munt, Jennifer E. Garrido, Carolina Lindesmith, Lisa Watanabe, Jennifer Usachenko, Jodie L. Hopkins, Lincoln Immareddy, Ramya Lakshmanappa, Yashavanth Shaan Elizaldi, Sonny R. Roh, Jamin W. Sammak, Rebecca L. Pollard, Rachel E. Yee, JoAnn L. Herbek, Savannah Scobey, Trevor Miehlke, Dieter Fouda, Genevieve Ferrari, Guido Gao, Hongmei Shen, Xiaoying Kozlowski, Pamela A. Montefiori, David Hudgens, Michael G. Edwards, Darin K. Carfi, Andrea Corbett, Kizzmekia S. Graham, Barney S. Fox, Christopher B. Tomai, Mark Iyer, Smita S. Baric, Ralph Reader, Rachel Dittmer, Dirk P. Van Rompay, Koen K.A. Permar, Sallie R. De Paris, Kristina |
author_sort | Milligan, Emma C. |
collection | PubMed |
description | The U.S. Food and Drug Administration only gave emergency-use-authorization of the BNT162b2 and the mRNA-1273 SARS-CoV-2 vaccines for infants 6 months and older in June 2022. Yet, questions regarding the durability of vaccine efficacy, especially against emerging variants, in this age group remain. We demonstrated previously that a two-dose regimen of stabilized prefusion Washington SARS-CoV-2 S-2P spike (S) protein encoded by mRNA encapsulated in lipid nanoparticles (mRNA-LNP) or purified S-2P mixed with 3 M-052, a synthetic toll-like receptor (TLR) 7/8 agonist, in a squalene emulsion (Protein+3 M-052-SE) was safe and immunogenic in infant rhesus macaques. Here, we demonstrate that broadly neutralizing and spike-binding antibodies against variants of concern (VOC), as well as T cell responses, persisted for 12 months. At one year, corresponding to human toddler age, we challenged vaccinated rhesus macaques and age-matched non-vaccinated controls intranasally and intratracheally with a high-dose of heterologous SARS-CoV-2 B.1.617.2 (Delta). Seven of eight control rhesus macaques exhibited severe interstitial pneumonia and high virus replication in the upper and lower respiratory tract. In contrast, vaccinated rhesus macaques had faster viral clearance with mild to no pneumonia. Neutralizing and binding antibody responses to the B.1.617.2 variant at the day of challenge correlated with lung pathology and reduced virus replication. Overall, the Protein+3 M-052-SE vaccine provided superior protection to the mRNA-LNP vaccine, emphasizing opportunities for optimization of current vaccine platforms. Notably, the observed efficacy of both vaccines one year after vaccination supports the implementation of an early life SARS-CoV-2 vaccine. |
format | Online Article Text |
id | pubmed-9765459 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Association for the Advancement of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-97654592022-12-22 Infant rhesus macaques immunized against SARS-CoV-2 are protected against heterologous virus challenge one year later Milligan, Emma C. Olstad, Katherine Williams, Caitlin A. Mallory, Michael Cano, Patricio Cross, Kaitlyn A. Munt, Jennifer E. Garrido, Carolina Lindesmith, Lisa Watanabe, Jennifer Usachenko, Jodie L. Hopkins, Lincoln Immareddy, Ramya Lakshmanappa, Yashavanth Shaan Elizaldi, Sonny R. Roh, Jamin W. Sammak, Rebecca L. Pollard, Rachel E. Yee, JoAnn L. Herbek, Savannah Scobey, Trevor Miehlke, Dieter Fouda, Genevieve Ferrari, Guido Gao, Hongmei Shen, Xiaoying Kozlowski, Pamela A. Montefiori, David Hudgens, Michael G. Edwards, Darin K. Carfi, Andrea Corbett, Kizzmekia S. Graham, Barney S. Fox, Christopher B. Tomai, Mark Iyer, Smita S. Baric, Ralph Reader, Rachel Dittmer, Dirk P. Van Rompay, Koen K.A. Permar, Sallie R. De Paris, Kristina Sci Transl Med Research Articles The U.S. Food and Drug Administration only gave emergency-use-authorization of the BNT162b2 and the mRNA-1273 SARS-CoV-2 vaccines for infants 6 months and older in June 2022. Yet, questions regarding the durability of vaccine efficacy, especially against emerging variants, in this age group remain. We demonstrated previously that a two-dose regimen of stabilized prefusion Washington SARS-CoV-2 S-2P spike (S) protein encoded by mRNA encapsulated in lipid nanoparticles (mRNA-LNP) or purified S-2P mixed with 3 M-052, a synthetic toll-like receptor (TLR) 7/8 agonist, in a squalene emulsion (Protein+3 M-052-SE) was safe and immunogenic in infant rhesus macaques. Here, we demonstrate that broadly neutralizing and spike-binding antibodies against variants of concern (VOC), as well as T cell responses, persisted for 12 months. At one year, corresponding to human toddler age, we challenged vaccinated rhesus macaques and age-matched non-vaccinated controls intranasally and intratracheally with a high-dose of heterologous SARS-CoV-2 B.1.617.2 (Delta). Seven of eight control rhesus macaques exhibited severe interstitial pneumonia and high virus replication in the upper and lower respiratory tract. In contrast, vaccinated rhesus macaques had faster viral clearance with mild to no pneumonia. Neutralizing and binding antibody responses to the B.1.617.2 variant at the day of challenge correlated with lung pathology and reduced virus replication. Overall, the Protein+3 M-052-SE vaccine provided superior protection to the mRNA-LNP vaccine, emphasizing opportunities for optimization of current vaccine platforms. Notably, the observed efficacy of both vaccines one year after vaccination supports the implementation of an early life SARS-CoV-2 vaccine. American Association for the Advancement of Science 2022-12-01 /pmc/articles/PMC9765459/ /pubmed/36454813 http://dx.doi.org/10.1126/scitranslmed.add6383 Text en Copyright © 2022 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution License 4.0 (CC BY). https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution license (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Articles Milligan, Emma C. Olstad, Katherine Williams, Caitlin A. Mallory, Michael Cano, Patricio Cross, Kaitlyn A. Munt, Jennifer E. Garrido, Carolina Lindesmith, Lisa Watanabe, Jennifer Usachenko, Jodie L. Hopkins, Lincoln Immareddy, Ramya Lakshmanappa, Yashavanth Shaan Elizaldi, Sonny R. Roh, Jamin W. Sammak, Rebecca L. Pollard, Rachel E. Yee, JoAnn L. Herbek, Savannah Scobey, Trevor Miehlke, Dieter Fouda, Genevieve Ferrari, Guido Gao, Hongmei Shen, Xiaoying Kozlowski, Pamela A. Montefiori, David Hudgens, Michael G. Edwards, Darin K. Carfi, Andrea Corbett, Kizzmekia S. Graham, Barney S. Fox, Christopher B. Tomai, Mark Iyer, Smita S. Baric, Ralph Reader, Rachel Dittmer, Dirk P. Van Rompay, Koen K.A. Permar, Sallie R. De Paris, Kristina Infant rhesus macaques immunized against SARS-CoV-2 are protected against heterologous virus challenge one year later |
title | Infant rhesus macaques immunized against SARS-CoV-2 are protected against heterologous virus challenge one year later |
title_full | Infant rhesus macaques immunized against SARS-CoV-2 are protected against heterologous virus challenge one year later |
title_fullStr | Infant rhesus macaques immunized against SARS-CoV-2 are protected against heterologous virus challenge one year later |
title_full_unstemmed | Infant rhesus macaques immunized against SARS-CoV-2 are protected against heterologous virus challenge one year later |
title_short | Infant rhesus macaques immunized against SARS-CoV-2 are protected against heterologous virus challenge one year later |
title_sort | infant rhesus macaques immunized against sars-cov-2 are protected against heterologous virus challenge one year later |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9765459/ https://www.ncbi.nlm.nih.gov/pubmed/36454813 http://dx.doi.org/10.1126/scitranslmed.add6383 |
work_keys_str_mv | AT milliganemmac infantrhesusmacaquesimmunizedagainstsarscov2areprotectedagainstheterologousviruschallengeoneyearlater AT olstadkatherine infantrhesusmacaquesimmunizedagainstsarscov2areprotectedagainstheterologousviruschallengeoneyearlater AT williamscaitlina infantrhesusmacaquesimmunizedagainstsarscov2areprotectedagainstheterologousviruschallengeoneyearlater AT mallorymichael infantrhesusmacaquesimmunizedagainstsarscov2areprotectedagainstheterologousviruschallengeoneyearlater AT canopatricio infantrhesusmacaquesimmunizedagainstsarscov2areprotectedagainstheterologousviruschallengeoneyearlater AT crosskaitlyna infantrhesusmacaquesimmunizedagainstsarscov2areprotectedagainstheterologousviruschallengeoneyearlater AT muntjennifere infantrhesusmacaquesimmunizedagainstsarscov2areprotectedagainstheterologousviruschallengeoneyearlater AT garridocarolina infantrhesusmacaquesimmunizedagainstsarscov2areprotectedagainstheterologousviruschallengeoneyearlater AT lindesmithlisa infantrhesusmacaquesimmunizedagainstsarscov2areprotectedagainstheterologousviruschallengeoneyearlater AT watanabejennifer infantrhesusmacaquesimmunizedagainstsarscov2areprotectedagainstheterologousviruschallengeoneyearlater AT usachenkojodiel infantrhesusmacaquesimmunizedagainstsarscov2areprotectedagainstheterologousviruschallengeoneyearlater AT hopkinslincoln infantrhesusmacaquesimmunizedagainstsarscov2areprotectedagainstheterologousviruschallengeoneyearlater AT immareddyramya infantrhesusmacaquesimmunizedagainstsarscov2areprotectedagainstheterologousviruschallengeoneyearlater AT lakshmanappayashavanthshaan infantrhesusmacaquesimmunizedagainstsarscov2areprotectedagainstheterologousviruschallengeoneyearlater AT elizaldisonnyr infantrhesusmacaquesimmunizedagainstsarscov2areprotectedagainstheterologousviruschallengeoneyearlater AT rohjaminw infantrhesusmacaquesimmunizedagainstsarscov2areprotectedagainstheterologousviruschallengeoneyearlater AT sammakrebeccal infantrhesusmacaquesimmunizedagainstsarscov2areprotectedagainstheterologousviruschallengeoneyearlater AT pollardrachele infantrhesusmacaquesimmunizedagainstsarscov2areprotectedagainstheterologousviruschallengeoneyearlater AT yeejoannl infantrhesusmacaquesimmunizedagainstsarscov2areprotectedagainstheterologousviruschallengeoneyearlater AT herbeksavannah infantrhesusmacaquesimmunizedagainstsarscov2areprotectedagainstheterologousviruschallengeoneyearlater AT scobeytrevor infantrhesusmacaquesimmunizedagainstsarscov2areprotectedagainstheterologousviruschallengeoneyearlater AT miehlkedieter infantrhesusmacaquesimmunizedagainstsarscov2areprotectedagainstheterologousviruschallengeoneyearlater AT foudagenevieve infantrhesusmacaquesimmunizedagainstsarscov2areprotectedagainstheterologousviruschallengeoneyearlater AT ferrariguido infantrhesusmacaquesimmunizedagainstsarscov2areprotectedagainstheterologousviruschallengeoneyearlater AT gaohongmei infantrhesusmacaquesimmunizedagainstsarscov2areprotectedagainstheterologousviruschallengeoneyearlater AT shenxiaoying infantrhesusmacaquesimmunizedagainstsarscov2areprotectedagainstheterologousviruschallengeoneyearlater AT kozlowskipamelaa infantrhesusmacaquesimmunizedagainstsarscov2areprotectedagainstheterologousviruschallengeoneyearlater AT montefioridavid infantrhesusmacaquesimmunizedagainstsarscov2areprotectedagainstheterologousviruschallengeoneyearlater AT hudgensmichaelg infantrhesusmacaquesimmunizedagainstsarscov2areprotectedagainstheterologousviruschallengeoneyearlater AT edwardsdarink infantrhesusmacaquesimmunizedagainstsarscov2areprotectedagainstheterologousviruschallengeoneyearlater AT carfiandrea infantrhesusmacaquesimmunizedagainstsarscov2areprotectedagainstheterologousviruschallengeoneyearlater AT corbettkizzmekias infantrhesusmacaquesimmunizedagainstsarscov2areprotectedagainstheterologousviruschallengeoneyearlater AT grahambarneys infantrhesusmacaquesimmunizedagainstsarscov2areprotectedagainstheterologousviruschallengeoneyearlater AT foxchristopherb infantrhesusmacaquesimmunizedagainstsarscov2areprotectedagainstheterologousviruschallengeoneyearlater AT tomaimark infantrhesusmacaquesimmunizedagainstsarscov2areprotectedagainstheterologousviruschallengeoneyearlater AT iyersmitas infantrhesusmacaquesimmunizedagainstsarscov2areprotectedagainstheterologousviruschallengeoneyearlater AT baricralph infantrhesusmacaquesimmunizedagainstsarscov2areprotectedagainstheterologousviruschallengeoneyearlater AT readerrachel infantrhesusmacaquesimmunizedagainstsarscov2areprotectedagainstheterologousviruschallengeoneyearlater AT dittmerdirkp infantrhesusmacaquesimmunizedagainstsarscov2areprotectedagainstheterologousviruschallengeoneyearlater AT vanrompaykoenka infantrhesusmacaquesimmunizedagainstsarscov2areprotectedagainstheterologousviruschallengeoneyearlater AT permarsallier infantrhesusmacaquesimmunizedagainstsarscov2areprotectedagainstheterologousviruschallengeoneyearlater AT depariskristina infantrhesusmacaquesimmunizedagainstsarscov2areprotectedagainstheterologousviruschallengeoneyearlater |